Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Follicular 10Sarcoma 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Rhabdoid Tumor 3Prostatic Neoplasms 3Wilms Tumor 2Sarcoma, Synovial 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Tertiary Lymphoid Structures 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1

Interventions

Dexamethasone 238Lenalidomide 145daratumumab 123Bortezomib 101pomalidomide 86Calcium Dobesilate 76carfilzomib 74Cyclophosphamide 70Specimen Handling 42isatuximab 40Biopsy 40fludarabine 36belantamab mafodotin 36Magnetic Resonance Spectroscopy 35talquetamab 29dexamethasone acetate 27dexamethasone 21-phosphate 27Melphalan 27auricularum 26iberdomide 25ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × tazemetostat × 1 year × Clear all
NCT05372354 2025-09-05

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb

Phase 1/2 Recruiting
260 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡